Barsness G W, Peterson E D, Ohman E M, Nelson C L, DeLong E R, Reves J G, Smith P K, Anderson R D, Jones R H, Mark D B, Califf R M
Duke Heart Center, Duke University Medical Center, Durham, NC, USA.
Circulation. 1997 Oct 21;96(8):2551-6. doi: 10.1161/01.cir.96.8.2551.
Recent subgroup analyses of randomized trials have suggested that percutaneous intervention in diabetic patients with multivessel disease results in higher mortality than coronary artery bypass graft surgery (CABG). We studied the relationship between diabetes and survival after revascularization in a large prospective cohort of patients with multivessel coronary artery disease.
By analyzing data for 3220 patients (24% diabetic) with symptomatic two- or three-vessel coronary disease who were undergoing percutaneous transluminal coronary angioplasty (PTCA) or CABG at Duke University Medical Center between 1984 and 1990, we found that at 5 years, unadjusted survival in the group of patients undergoing CABG was 74% in diabetics and 86% in nondiabetics. Similarly, 5-year survival among PTCA patients was 76% in diabetics and 88% in patients without diabetes. After adjustment for baseline characteristics, diabetic patients receiving either PTCA or CABG had significantly poorer survival than nondiabetics (chi2=43.56, P<.0001). Unlike previous studies, however, there was no significant differential effect of diabetes on outcome between patients treated with PTCA and those treated with CABG (chi2=0.01, P=.91).
Although diabetes was associated with a worse long-term outcome after both PTCA and CABG in patients with multivessel coronary artery disease, the effect of diabetes on prognosis was similar in both treatment groups. Thus, our findings support the concept that the choice of initial revascularization strategy should not be based exclusively on a history of diabetes but rather should rely on other factors, such as angiographic suitability and clinical status.
近期随机试验的亚组分析表明,多支血管病变的糖尿病患者接受经皮介入治疗后的死亡率高于冠状动脉旁路移植术(CABG)。我们在一个大型多支血管冠状动脉疾病前瞻性队列中研究了糖尿病与血运重建术后生存率之间的关系。
通过分析1984年至1990年间在杜克大学医学中心接受经皮腔内冠状动脉成形术(PTCA)或CABG的3220例有症状的双支或三支冠状动脉疾病患者(24%为糖尿病患者)的数据,我们发现,在5年时,接受CABG的患者组中,糖尿病患者的未调整生存率为74%,非糖尿病患者为86%。同样,PTCA患者中糖尿病患者的5年生存率为76%,非糖尿病患者为88%。在对基线特征进行调整后,接受PTCA或CABG的糖尿病患者的生存率显著低于非糖尿病患者(χ2=43.56,P<0.0001)。然而,与以往研究不同的是,糖尿病对接受PTCA治疗的患者和接受CABG治疗的患者的结局没有显著的差异影响(χ2=0.01,P=0.91)。
尽管在多支血管冠状动脉疾病患者中,糖尿病与PTCA和CABG术后较差的长期结局相关,但糖尿病对两个治疗组预后的影响相似。因此,我们的研究结果支持这样一个概念,即初始血运重建策略的选择不应仅基于糖尿病病史,而应依赖于其他因素,如血管造影的适宜性和临床状态。